Brandon Couillard
Stock Analyst at Wells Fargo
(4.20)
# 470
Out of 5,147 analysts
186
Total ratings
56.88%
Success rate
12.97%
Average return
Main Sectors:
Stocks Rated by Brandon Couillard
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTRA Natera | Maintains: Equal-Weight | $205 → $215 | $208.04 | +3.35% | 4 | Feb 27, 2026 | |
| A Agilent Technologies | Maintains: Overweight | $175 → $165 | $121.38 | +35.94% | 26 | Feb 26, 2026 | |
| RGEN Repligen | Maintains: Overweight | $190 → $180 | $128.73 | +39.83% | 4 | Feb 25, 2026 | |
| CDNA CareDx | Maintains: Equal-Weight | $18 → $21 | $18.76 | +11.94% | 5 | Feb 25, 2026 | |
| MYGN Myriad Genetics | Maintains: Equal-Weight | $6.5 → $6 | $4.61 | +30.15% | 4 | Feb 24, 2026 | |
| GH Guardant Health | Maintains: Overweight | $120 → $125 | $93.90 | +33.12% | 3 | Feb 20, 2026 | |
| AVTR Avantor | Maintains: Overweight | $16 → $14 | $9.05 | +54.70% | 6 | Feb 13, 2026 | |
| WAT Waters | Maintains: Equal-Weight | $415 → $355 | $319.38 | +11.15% | 8 | Feb 11, 2026 | |
| WGS GeneDx Holdings | Upgrades: Overweight | $155 | $79.71 | +94.45% | 7 | Feb 9, 2026 | |
| TECH Bio-Techne | Maintains: Overweight | $70 → $76 | $59.00 | +28.81% | 3 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $83 → $94 | $96.57 | -2.66% | 5 | Feb 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $107 → $110 | $98.31 | +11.89% | 4 | Feb 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $635 → $675 | $521.11 | +29.53% | 8 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $1,450 | $1,366.69 | +6.10% | 7 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $4.5 | $3.56 | +26.40% | 2 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $230 → $240 | $210.64 | +13.94% | 5 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $55 | $40.11 | +37.12% | 7 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $110 | $76.33 | +44.11% | 1 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $90 → $105 | $103.38 | +1.57% | 19 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $265 → $340 | $278.44 | +22.11% | 13 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $265 → $340 | $267.56 | +27.07% | 13 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $285 → $260 | $190.10 | +36.77% | 11 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $77 → $80 | $82.39 | -2.90% | 6 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $30 → $23 | $29.21 | -21.26% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $2.42 | +437.19% | 1 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $3.15 | - | 11 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $11 | $1.01 | +989.11% | 2 | Oct 13, 2017 |
Natera
Feb 27, 2026
Maintains: Equal-Weight
Price Target: $205 → $215
Current: $208.04
Upside: +3.35%
Agilent Technologies
Feb 26, 2026
Maintains: Overweight
Price Target: $175 → $165
Current: $121.38
Upside: +35.94%
Repligen
Feb 25, 2026
Maintains: Overweight
Price Target: $190 → $180
Current: $128.73
Upside: +39.83%
CareDx
Feb 25, 2026
Maintains: Equal-Weight
Price Target: $18 → $21
Current: $18.76
Upside: +11.94%
Myriad Genetics
Feb 24, 2026
Maintains: Equal-Weight
Price Target: $6.5 → $6
Current: $4.61
Upside: +30.15%
Guardant Health
Feb 20, 2026
Maintains: Overweight
Price Target: $120 → $125
Current: $93.90
Upside: +33.12%
Avantor
Feb 13, 2026
Maintains: Overweight
Price Target: $16 → $14
Current: $9.05
Upside: +54.70%
Waters
Feb 11, 2026
Maintains: Equal-Weight
Price Target: $415 → $355
Current: $319.38
Upside: +11.15%
GeneDx Holdings
Feb 9, 2026
Upgrades: Overweight
Price Target: $155
Current: $79.71
Upside: +94.45%
Bio-Techne
Feb 6, 2026
Maintains: Overweight
Price Target: $70 → $76
Current: $59.00
Upside: +28.81%
Feb 4, 2026
Maintains: Equal-Weight
Price Target: $83 → $94
Current: $96.57
Upside: -2.66%
Feb 3, 2026
Maintains: Equal-Weight
Price Target: $107 → $110
Current: $98.31
Upside: +11.89%
Dec 15, 2025
Maintains: Overweight
Price Target: $635 → $675
Current: $521.11
Upside: +29.53%
Dec 15, 2025
Maintains: Equal-Weight
Price Target: $1,400 → $1,450
Current: $1,366.69
Upside: +6.10%
Dec 15, 2025
Maintains: Overweight
Price Target: $4 → $4.5
Current: $3.56
Upside: +26.40%
Dec 15, 2025
Maintains: Equal-Weight
Price Target: $230 → $240
Current: $210.64
Upside: +13.94%
Dec 15, 2025
Maintains: Overweight
Price Target: $48 → $55
Current: $40.11
Upside: +37.12%
Dec 1, 2025
Initiates: Equal-Weight
Price Target: $110
Current: $76.33
Upside: +44.11%
Nov 24, 2025
Downgrades: Hold
Price Target: $90 → $105
Current: $103.38
Upside: +1.57%
Oct 30, 2025
Maintains: Equal-Weight
Price Target: $265 → $340
Current: $278.44
Upside: +22.11%
Oct 30, 2025
Maintains: Equal-Weight
Price Target: $265 → $340
Current: $267.56
Upside: +27.07%
Jan 23, 2025
Maintains: Buy
Price Target: $285 → $260
Current: $190.10
Upside: +36.77%
Jan 23, 2025
Maintains: Hold
Price Target: $77 → $80
Current: $82.39
Upside: -2.90%
Feb 9, 2024
Downgrades: Hold
Price Target: $30 → $23
Current: $29.21
Upside: -21.26%
Jul 13, 2021
Initiates: Buy
Price Target: $13
Current: $2.42
Upside: +437.19%
Nov 2, 2017
Downgrades: Hold
Price Target: n/a
Current: $3.15
Upside: -
Oct 13, 2017
Maintains: Buy
Price Target: $9 → $11
Current: $1.01
Upside: +989.11%